Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03364231 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
A Phase 2 study of Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT03364231 is a Phase 2 study of Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia that has completed, run by TG Therapeutics. The registered enrollment target is 21 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03364231, a Phase 2 study of Marginal Zone Lymphoma and Waldenstrom Macroglobulinemia, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.
Conditions Studied
Interventions
- DRUG Umbralisib
Study Locations (4)
District of Columbia
- TG Therapeutics Investigational Trial Site - Washington D.C.
Massachusetts
- TG Therapeutics Investigational Trial Site - Boston
New Jersey
- TG Therapeutics Investigational Trial Site - Hackensack
New York
- TG Therapeutics Investigational Trial Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2022-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03364231
The ClinicalTrials.gov registry entry for NCT03364231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (79% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Umbralisib is the first listed.
NCT03364231 reports 4 study locations spanning 4 distinct geographic areas - top geographies include District of Columbia, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03364231 about?
NCT03364231 is a clinical study titled "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma". This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.
What is the current status of trial NCT03364231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-11-30. Estimated completion is 2022-02-15.
What conditions does trial NCT03364231 study?
This clinical trial studies the following conditions: Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT03364231?
The interventions under investigation include: Umbralisib (DRUG).
Who is sponsoring clinical trial NCT03364231?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03364231 being conducted?
This trial has 4 study locations across District of Columbia, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marginal Zone Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RECRUITING · Phase 2
-
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RECRUITING · Phase 2
Explore more on PlainTrial
Marginal Zone Lymphoma
All registered trials for this condition
Waldenstrom Macroglobulinemia
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.